WilmerHale Advises Enavate Sciences on Its Investment in Braveheart Bio

WilmerHale Advises Enavate Sciences on Its Investment in Braveheart Bio

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Providing comprehensive solutions for the acquisition, enforcement and protection of IP.

WilmerHale advised Enavate Sciences (a platform of Patient Square Capital) on its investment in Braveheart Bio, a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM) and related conditions, in connection with its launch and $185 million Series A financing.

The WilmerHale team was led by Palo Alto partner Daniel Zimmermann, with associate Ben Goldfein. Palo Alto partner Jekkie Kim provided advice on intellectual property and licensing matters. 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel